Highly integrated miniaturised total analysis systems for pharmaceuticals in biological and environmental samples

高度集成的小型化生物和环境样品中药物的全面分析系统

• 批准号: FT130100101
• 负责人: Prof Michael Breadmore
• 金额: $ 60.83万
• 依托单位: University of Tasmania
• 依托单位国家: 澳大利亚
• 项目类别: ARC Future Fellowships
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/FT130100101
• 关键词: Highly; integrated; miniaturised; total; analysis

This project will develop three unique chemical approaches that will each overcome a challenge to the creation of advanced miniaturised analytical devices with sample-in/answer-out capability. This will provide substantial improvements in speed, cost, portability, and operational simplicity and safety. New technology for analysing drugs in body fluids will be critical to enabling people to closely match their pharmaceutical consumption with their individual requirements. The advance will have implications for all patients, particularly those in remote and rural Australian populations. The same technology is likely to find applications in environmental monitoring of emerging pharmaceutical pollutants.

该项目将开发三种独特的化学方法，每种方法都将克服创造具有样品输入/输出能力的先进自动化分析设备的挑战。这将在速度、成本、便携性以及操作简单性和安全性方面提供实质性的改进。分析体液中药物的新技术对于使人们能够将其药物消费与个人需求紧密匹配至关重要。这一进展将对所有患者产生影响，特别是那些偏远和农村的澳大利亚人口。同样的技术很可能在新兴药物污染物的环境监测中得到应用。